Licensed vaccine
PRIORIX
FDA-licensed vaccine · GlaxoSmithKline Biologicals SA · STN 125748
Key facts
| Trade name | PRIORIX |
|---|---|
| Proper name | Measles, Mumps and Rubella Vaccine, Live |
| Manufacturer | GlaxoSmithKline Biologicals SA |
| Submission tracking number (STN) | 125748 |
| Recent FDA documents | Demographic Subgroup Information – Measles, Mumps and Rubella Vaccine, Live (PRIORIX), Approval History, Letters, Reviews and Related Documents - PRIORIX, June 3, 2022 Summary Basis for Regulatory Action - PRIORIX, June 3, 2022 Approval Letter - PRIORIX, Package Insert - PRIORIX |
| FDA page updated | Jul 1, 2022 |
| FDA product page | fda.gov |
At a glance
- 1–9 FDA approval letters
- 1–9 Supporting documents
- 1–9 Product information documents
- Yes Document full text searchable in Orca1
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About FDA-licensed vaccines
The FDA's CBER licenses vaccines for use in the United States. Each product page links the approval letters, package inserts and supporting documents for that vaccine.
Source: U.S. Food and Drug Administration (FDA), Center for Biologics Evaluation and Research (CBER), Vaccines Licensed for Use in the United States · Source date: